| 2. Reperfusion strategy |
| 2.1 Proportion of patients with STEMI arriving in the first 12 hours who receiving reperfusion therapy |
50/91 |
70/113 |
0.31 |
| 2.2 For patients treated with fibrinolysis: <30 min from diagnosis to the needle |
2/50 |
11/70 |
0.04 |
| 4. In-hospital antithrombotic drugs |
| 4.1. Number of patients eligible for in-hospital antithrombotic therapies who received ≥ 1 therapies. |
101/101 |
123/123 |
1.0 |
| 4.2. Dual antiplatelet therapy |
93/101 |
114/123 |
0.86 |
| 5. Secondary prevention discharge treatment |
| 5.1 Proportion of patients with AMI discharged on statins, unless contraindicated |
66/80 |
103/105 |
≤ 0.01 |
| 5.2 Proportion of patients with LVEF equal or less to 40% or clinical evidence of heart failure, with betablocker prescribed at discharge |
13/17 |
13/17 |
1.0 |
| 5.3 Proportion of patients with LVEF equal or less to 40% or clinical evidence of heart failure, with ACE inhibitor prescribed at discharge |
15/17 |
17/17 |
0.14 |
| 5.4 Proportion of patients with smoking cessation advice at discharge |
23/35 |
42/45 |
0.02 |
| 5.5 Proportion of patients enrolled in secondary prevention programs |
10/70 |
17/105 |
0.73 |
| 7. Outcome measures |
| In-hospital mortality rate |
21/101 |
18/123 |
0.22 |
| 30-day adjusted readmission rate |
3/101 |
3/123 |
0.8 |
| 8. Composite quality indicator |
| Proportion of patients with LVEF equal or less to 40% or clinical evidence of heart failure, with DAPT and statins prescribed at discharge |
15/17 |
17/17 |
0.14 |
| Proportion of patients with LVEF equal or less to 40% or clinical evidence of heart failure, with betablocker, ACE-I, DAPT, and statins prescribed at discharge |
12/17 |
13/17 |
0.69 |
